FIBROBIOLOGICS INC
FBLGNASDAQTrading Snapshot
- Day Range
- $1.35 – $1.38
- 52-Week Range
- $0.62 – $12.40
- Volume
- $1.94B
- Avg Volume
- $2.42B
- Shares Outstanding
- 2.1M
- Next Earnings
- Dec 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $303,247
- Last Q Revenue
- $83,384
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.81
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +91.3%
Why Investors Own FBLG
- ✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FIBROBIOLOGICS INC
FBLG
StockOtter · stockotter.spaceAbout FIBROBIOLOGICS INC
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration HOUSTON, Sept. 29, 20
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nas
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foo